A new treatment option is now available for moderately to severely active Ulcerative Colitis (UC). This new drug tofacitinib is the 1st & only JAK inhibitor registered for UC. Tofacitinib is an oral small molecule, targeting inflammation from inside the cell. This introduction marks a new era in the treatment of UC. The efficacy and safety of tofacitinib has been established in an extensive clinical trial program, and the emerging Real World data confirms this profile to date. The two available doses and the short half-life allow for a practical treatment flexibility of your UC patients.
Learn more about tofacitinib with Professor Séverine Vermeire from UZ Leuven, who has extensive clinical trial and real-world experience with this innovative new treatment in UC.
Dermatology
Accrédité pour médecins (N° 25034524 - 1 point)
Rhumatology & Orthopedy
Accrédité pour médecins (N° - point)
Healthcare
Accrédité pour 'autres' (N° 26000450001 - 1 point)
Accrédité pour les médecins - 25034524 - 1CP
